Thursday, May 09, 2019 12:00:05 PM
Item 1.01. Entry Into a Material Definitive Agreement.
On May 6, 2019, Bioxytran, Inc. (“Bioxytran”) and Asclepius LLC entered into a one-year Scientific Advisory Board Agreement, effective as of May 1, 2018 (the “Scientific Advisory Board Agreement”) whereby Juan Carlos Lopez Talavera (“Advisor”) will serve as a member of Bioxytran’s Scientific Advisory Board. Advisor will provide assistance and advice to the company in his field of expertise as a developer of pharmaceutical compounds and mentor Bioxytran’s through the Food and Drug Administration’s regulatory submission and approval process. Advisor will commit such time as possible without interfering with his existing duties with his current employer but in no event more than 20 days per year.
As compensation for his services, Bioxytran will issue Advisor options to purchase up to 45,000 shares of Bioxytran’s common stock, par value $0.01 per share (the “Common Stock”), under the Company’s 2010 Employee, Director and Consultant Stock Plan, or any successor plan thereto, at the beginning of each successive quarter of service, exercisable at a price equal to 110% of the market price of Bioxytran’s Common Stock on the date of issuance. In addition, Bioxytran will pay for Advisor’s expenses up to $500 per quarter. The Scientific Advisory Agreement may be terminated by either party with 30 days prior written notice. Upon termination of the Scientific Advisory Board Agreement, Advisor shall receive payment for services performed and expenses paid or incurred prior to the date of termination. The Scientific Advisory Board Agreement also contains protection for Bioxytran’s intellectual property and for the intellectual property of Advisor’s employer.
The foregoing description of the Scientific Advisory Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the form of Scientific Advisory Agreement, which is filed as Exhibit 10.24 to this Current Report on Form 8-K and incorporated herein by reference.
Item 8.01. Other Events.
On May 6, 2019, Bioxytran issued a press release announcing that Juan Carlos Lopez Talavera, former Bristol-Myers Squibb executive joined Bioxytran’s Scientific Advisory Board.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit
Number Description
10.24 Scientific Advisory Board Agreement between Bioxytran, Inc. and Asclepius LLC dated May 1, 2019.
99.1 Press Release dated May 6, 2019.
By: /s/ Dr. David Platt
Name: Dr. David Platt
Title: President and Chief Executive Officer
Dated: May 6, 2019
Recent BIXT News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/20/2024 10:02:35 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/20/2024 09:59:22 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/20/2024 09:30:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/20/2024 08:52:36 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/20/2024 08:39:14 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2024 09:00:57 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/17/2024 10:02:27 AM
- Form RW - Registration Withdrawal Request • Edgar (US Regulatory) • 07/08/2024 10:03:37 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 08:43:10 PM
- Form 5 - Annual statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/16/2024 03:09:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/03/2023 01:05:31 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/03/2023 01:02:24 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/10/2023 10:34:21 AM
- Form 424B4 - Prospectus [Rule 424(b)(4)] • Edgar (US Regulatory) • 10/02/2023 03:36:43 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 09/26/2023 09:04:03 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM